Literature DB >> 12734385

Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization.

Mirko H H Schmidt1, Frank B Furnari, Webster K Cavenee, Oliver Bögler.   

Abstract

Ligand activation of the epidermal growth factor receptor (EGFR) causes the binding of Cbls, which leads to EGFR polyubiquitination and internalization through endophilin complexes that contain the adaptor protein SH3-domain encoding, expressed in tumorigenic astrocytes/Cbl-interacting protein of 85 kDa/regulator of ubiquitous kinase (SETA/CIN85/Ruk). In cells grown at high density, high levels of SETA interfered in the recruitment of Casitas B-lineage (Cbl) proteins to the EGFR and reduced its polyubiquitination, suggesting that SETA has a regulatory function in the formation of the EGFR-Cbl-endophilin complex and in EGFR down-regulation. In a situation where there is EGFR signaling but no internalization or down-regulation, as is the case with the EGFR with exons 2-7 deleted (DeltaEGFR) oncogene, these proteins were absent altogether. By using mAb 806, which recognizes an EGFR-activation state and preferentially immunoprecipitates DeltaEGFR, we show that DeltaEGFR did not interact with Cbls, SETA, or endophilin A1, providing a mechanistic explanation for its lack of internalization. As would be expected by the absence of Cbl proteins in the DeltaEGFR complex, the mutant receptor was also not polyubiquitinated. The intracellular C terminus and tyrosine autophosphorylation pattern of DeltaEGFR are similar to wild-type EGFR, but it signals at a lower intensity as determined by levels of EGFR phosphotyrosine. To test the implication that the lack of interaction with the Cbl-SETA-endophilin complex is because of differences in signal intensity, EGFR-expressing cells were treated with tyrphostin AG1478 EGFR inhibitor. Attenuation of wild-type EGFR signal to levels similar to that found in DeltaEGFR resulted in the dissociation of SETA and Cbl proteins and a concomitant attenuation of receptor internalization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734385      PMCID: PMC164476          DOI: 10.1073/pnas.1031790100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Cloning and characterization of a novel adaptor protein, CIN85, that interacts with c-Cbl.

Authors:  H Take; S Watanabe; K Takeda; Z X Yu; N Iwata; S Kajigaya
Journal:  Biochem Biophys Res Commun       Date:  2000-02-16       Impact factor: 3.575

2.  Negative regulation of PI 3-kinase by Ruk, a novel adaptor protein.

Authors:  I Gout; G Middleton; J Adu; N N Ninkina; L B Drobot; V Filonenko; G Matsuka; A M Davies; M Waterfield; V L Buchman
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

3.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.

Authors:  N Sugawa; A J Ekstrand; C D James; V P Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

4.  Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1.

Authors:  G Levkowitz; H Waterman; S A Ettenberg; M Katz; A Y Tsygankov; I Alroy; S Lavi; K Iwai; Y Reiss; A Ciechanover; S Lipkowitz; Y Yarden
Journal:  Mol Cell       Date:  1999-12       Impact factor: 17.970

5.  cbl-b inhibits EGF-receptor-induced apoptosis by enhancing ubiquitination and degradation of activated receptors.

Authors:  S A Ettenberg; Y R Rubinstein; P Banerjee; M M Nau; M M Keane; S Lipkowitz
Journal:  Mol Cell Biol Res Commun       Date:  1999-08

6.  The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation.

Authors:  P S Lee; Y Wang; M G Dominguez; Y G Yeung; M A Murphy; D D Bowtell; E R Stanley
Journal:  EMBO J       Date:  1999-07-01       Impact factor: 11.598

7.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

8.  Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.

Authors:  P A Humphrey; A J Wong; B Vogelstein; M R Zalutsky; G N Fuller; G E Archer; H S Friedman; M M Kwatra; S H Bigner; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

9.  The glioma-associated protein SETA interacts with AIP1/Alix and ALG-2 and modulates apoptosis in astrocytes.

Authors:  B Chen; S C Borinstein; J Gillis; V W Sykes; O Bogler
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

10.  Characterization of the CIN85 adaptor protein and identification of components involved in CIN85 complexes.

Authors:  S Watanabe; H Take; K Takeda; Z X Yu; N Iwata; S Kajigaya
Journal:  Biochem Biophys Res Commun       Date:  2000-11-11       Impact factor: 3.575

View more
  62 in total

1.  Ubiquitination-dependent regulation of signaling receptors in cancer.

Authors:  Wei-Chun Huangfu; Serge Y Fuchs
Journal:  Genes Cancer       Date:  2010-07

2.  Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation.

Authors:  Qian Wang; Greg Villeneuve; Zhixiang Wang
Journal:  EMBO Rep       Date:  2005-10       Impact factor: 8.807

3.  Analysis of receptor tyrosine kinase internalization using flow cytometry.

Authors:  Ning Li; Kristen S Hill; Lisa A Elferink
Journal:  Methods Mol Biol       Date:  2008

Review 4.  Endosomes: a legitimate platform for the signaling train.

Authors:  Jane E Murphy; Benjamin E Padilla; Burcu Hasdemir; Graeme S Cottrell; Nigel W Bunnett
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

5.  EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.

Authors:  Alison Roos; Harshil D Dhruv; Sen Peng; Landon J Inge; Serdar Tuncali; Michael Pineda; Nghia Millard; Zachary Mayo; Jennifer M Eschbacher; Joseph C Loftus; Jeffrey A Winkles; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2018-05-03       Impact factor: 5.852

6.  Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity.

Authors:  German G Gomez; Stefano Volinia; Carlo M Croce; Ciro Zanca; Ming Li; Ryan Emnett; David H Gutmann; Cameron W Brennan; Frank B Furnari; Webster K Cavenee
Journal:  Cancer Res       Date:  2014-01-16       Impact factor: 12.701

Review 7.  Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.

Authors:  Byung Min Chung; Eric Tom; Neha Zutshi; Timothy Alan Bielecki; Vimla Band; Hamid Band
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Identification of a novel small molecule HIF-1alpha translation inhibitor.

Authors:  Takuhito Narita; Shaoman Yin; Christine F Gelin; Carlos S Moreno; Manuel Yepes; K C Nicolaou; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

9.  I-BAR protein antagonism of endocytosis mediates directional sensing during guided cell migration.

Authors:  Gabriel A Quinones; Janet Jin; Anthony E Oro
Journal:  J Cell Biol       Date:  2010-04-12       Impact factor: 10.539

10.  Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway.

Authors:  Richard J Orton; Michiel E Adriaens; Amelie Gormand; Oliver E Sturm; Walter Kolch; David R Gilbert
Journal:  BMC Syst Biol       Date:  2009-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.